Pavlovian Drug Discrimination with Bupropion As a Feature Positive Occasion Setter: Substitution by Methamphetamine and Nicotine, but Not Cocaine
Overview
Authors
Affiliations
Bupropion can serve as a discriminative stimulus (S(D)) in an operant drug discrimination task, and a variety of stimulants substitute for the bupropion S(D). There are no reports, however, of bupropion functioning as a Pavlovian occasion setter (i.e. feature positive modulator). The present experiment seeks to fill this gap in the literature by training bupropion in rats as a feature positive modulator that disambiguates when a light will be paired with sucrose. Specifically, on bupropion (10 mg/kg intraperitoneal) sessions, offset of 15-second cue lights were followed by brief delivery of liquid sucrose; saline sessions were similar except no sucrose was available. Rats readily acquired the discrimination with more conditioned responding to the light on bupropion sessions. Bupropion is approved for use as a smoking cessation aid, and more recently has drawn attention as a potential pharmacotherapy for cocaine and methamphetamine abuse. Accordingly, after discrimination training, we tested the ability of cocaine (1-10 mg/kg), methamphetamine (0.1 to 1 mg/kg) and nicotine (0.00625 to 0.2 mg/kg) to substitute for the bupropion feature. Nicotine (0.05 mg/kg) and methamphetamine (0.3 mg/kg) substituted fully for bupropion; cocaine did not substitute. These results extend previous research on shared stimulus properties between bupropion and other stimulants to a Pavlovian occasion setting function. Further, this is the first report of nicotine and methamphetamine substitution for bupropion. The overlap in stimulus properties might explain the effectiveness of bupropion as a smoking cessation aid and highlight the possible utility of bupropion for treatment of stimulant use disorder.
Use of the overexpectation effect to reduce conditioned seeking behavior controlled by nicotine.
Barrett S, Tracy M, Bevins R Psychon Bull Rev. 2024; 31(6):2758-2766.
PMID: 38769272 DOI: 10.3758/s13423-024-02524-1.
Peart D, Nolan C, Stone A, Williams M, Karlovcec J, Murray J Psychopharmacology (Berl). 2024; 241(8):1597-1615.
PMID: 38580732 DOI: 10.1007/s00213-024-06584-y.
McNealy K, Weyrich L, Bevins R Drug Alcohol Depend. 2023; 248:109906.
PMID: 37216808 PMC: 10361216. DOI: 10.1016/j.drugalcdep.2023.109906.
Barrett S, Flynn A, Huynh Y, Bevins R J Exp Anal Behav. 2022; 117(3):543-559.
PMID: 35192221 PMC: 9090954. DOI: 10.1002/jeab.740.
Interoception and alcohol: Mechanisms, networks, and implications.
Lovelock D, Tyler R, Besheer J Neuropharmacology. 2021; 200:108807.
PMID: 34562442 PMC: 8541934. DOI: 10.1016/j.neuropharm.2021.108807.